Exact Sciences Co. (NASDAQ:EXAS) Insider Jacob A. Orville Sells 1,696 Shares

Exact Sciences Co. (NASDAQ:EXAS) insider Jacob A. Orville sold 1,696 shares of the stock in a transaction dated Friday, February 19th. The stock was sold at an average price of $143.38, for a total transaction of $243,172.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

NASDAQ EXAS opened at $142.32 on Tuesday. The stock has a market capitalization of $24.07 billion, a price-to-earnings ratio of -64.40 and a beta of 1.64. Exact Sciences Co. has a one year low of $35.25 and a one year high of $159.54. The company has a debt-to-equity ratio of 0.68, a current ratio of 6.35 and a quick ratio of 6.04. The business’s fifty day moving average is $143.72 and its 200-day moving average is $115.91.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Monday, February 15th. The medical research company reported ($2.79) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($2.60). Exact Sciences had a negative return on equity of 11.71% and a negative net margin of 25.27%. Research analysts expect that Exact Sciences Co. will post -1.56 EPS for the current fiscal year.

A number of research analysts have recently commented on the stock. Oppenheimer increased their target price on shares of Exact Sciences from $115.00 to $150.00 in a report on Wednesday, October 28th. Canaccord Genuity raised their price objective on shares of Exact Sciences from $160.00 to $165.00 and gave the company a “buy” rating in a report on Tuesday, January 12th. They noted that the move was a valuation call. BTIG Research raised their price objective on shares of Exact Sciences from $140.00 to $155.00 in a report on Wednesday, October 28th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lowered shares of Exact Sciences from a “buy” rating to a “neutral” rating and raised their price objective for the company from $120.00 to $140.00 in a report on Wednesday, October 28th. Finally, Truist began coverage on shares of Exact Sciences in a report on Wednesday, January 27th. They set a “buy” rating and a $226.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Exact Sciences has a consensus rating of “Buy” and a consensus price target of $142.47.

Institutional investors have recently made changes to their positions in the stock. International Assets Investment Management LLC raised its stake in Exact Sciences by 6.0% in the 4th quarter. International Assets Investment Management LLC now owns 4,184 shares of the medical research company’s stock valued at $554,000 after acquiring an additional 237 shares during the period. Columbus Circle Investors bought a new stake in Exact Sciences in the 4th quarter valued at about $28,257,000. JGP Global Gestao de Recursos Ltda. raised its stake in Exact Sciences by 3.4% in the 4th quarter. JGP Global Gestao de Recursos Ltda. now owns 3,487 shares of the medical research company’s stock valued at $462,000 after acquiring an additional 114 shares during the period. Thrivent Financial for Lutherans bought a new stake in Exact Sciences in the 3rd quarter valued at about $207,000. Finally, California State Teachers Retirement System raised its stake in Exact Sciences by 2.3% in the 3rd quarter. California State Teachers Retirement System now owns 272,781 shares of the medical research company’s stock valued at $27,810,000 after acquiring an additional 6,194 shares during the period. Institutional investors and hedge funds own 90.39% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype MAP, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; and Covid-19 testing services.

Recommended Story: Return On Assets

Insider Buying and Selling by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.